<DOC>
	<DOCNO>NCT01086553</DOCNO>
	<brief_summary>This study aim evaluate efficacy 9 mg budesonide daily ( OD ) versus 3 mg budesonide three-times daily ( TID ) induction remission Crohn 's disease .</brief_summary>
	<brief_title>9 mg Budesonide Once Daily ( OD ) Versus 3 mg Budesonide Three Times Daily ( TID ) Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed informed consent , Age 18 75 year , Symptoms Crohn 's disease since least 3 month ; diagnosis confirm endoscopic histological , endoscopic radiological criterion [ endoscopy old 12 month old , clinical sign ( e.g. , pain localisation , pain intensity , blood stool ) behaviour ( accord Montreal classification ) unchanged compare former episode ] , Localisation CD either terminal ileum , coecum , ascend colon , ileocolitis , Active phase disease ( 200 &lt; CDAI &lt; 400 ) , Negative pregnancy test female childbearing potential , Women childbearing potential apply appropriate contraceptive method , e.g. , hormonal contraception , intrauterine device ( IUD ) , doublebarrier method contraception ( e.g. , use condom spermicide ) , partner undergone vasectomy . The investigator responsible determine whether subject adequate birth control study participation . Known Crohn 's lesion upper GItract ( include jejunum ) rectum present symptom , Septic complication , Evidence infectious diarrhoea ( i.e. , pathogenic bacteria stool culture ) , Abscess , perforation , active fistula , Ileostomy colostomy , Resection 50 cm ileum , Bowel surgery within last 3 month , Immediate surgery require ( e.g. , major stenosis , serious bleeding , peritonitis , ileus ) , Clinical sign stricturing disease , Subileus within last 6 month ( subileus inflammatory hint allow ) , Suspicion ileus , subileus corresponding symptom , Parenteral tube feeding , Active peptic ulcer disease , local intestinal infection , know establish cataract , Diabetes mellitus , infection , osteoporosis , glaucoma , tuberculosis , hypertension careful medical monitoring ensure , Abnormal hepatic function ( ALT ALP &gt; 2.5 x upper limit normal [ ULN ] ) , liver cirrhosis , portal hypertension , Abnormal renal function ( Cystatin C &gt; ULN ) , Any severe concomitant cardiovascular , renal , endocrine , psychiatric disorder , History cancer last five year ( except nonmetastatic cancer , e.g. , basalioma ) , Treatment immunosuppressants anticancer drug , e.g. , 6 TG , methotrexate , tacrolimus , cyclophosphamide , cyclosporine within last 3 month ; case treatment azathioprine 6 MP drug use maintenance remission dosage unchanged within last 3 month baseline visit study , Treatment ketoconazole CYP3A inhibitor within last month baseline visit , Treatment antiTNFalpha therapy within 3 month baseline visit , Conventional steroid ( iv , po , rectal ) within 2 week baseline visit , &gt; 6 mg/d budesonide po within 2 week baseline visit , Steroids inhalation within 2 week baseline visit , Patients know steroidrefractory , Treatment study disease oral antibiotic ( e.g. , metronidazole ciprofloxacin ) within last 2 week , Application nonsteroidal antiinflammatory drug ( NSAIDs ) within 2 week baseline visit except ≤ 350 mg/d shortterm acetylsalicylic acid ( paracetamol allow ) , Known intolerance/hypersensitivity study drug , Wellfounded doubt patient 's cooperation , e.g. , addiction alcohol drug , Existing intend pregnancy breastfeeding , Participation another clinical trial within last 30 day , simultaneous participation another clinical trial , previous participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Crohn´s disease</keyword>
	<keyword>budesonide</keyword>
	<keyword>induction remission</keyword>
</DOC>